FRANKLIN RESOURCES INC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.

Quarter-by-quarter ownership
FRANKLIN RESOURCES INC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$93,140,241
-18.7%
1,788,064
-1.1%
0.05%
-13.0%
Q2 2023$114,497,066
+18.0%
1,808,229
+0.9%
0.05%
+10.2%
Q1 2023$97,047,039
+2.3%
1,792,189
-0.1%
0.05%0.0%
Q4 2022$94,909,691
+13.5%
1,793,456
-0.2%
0.05%
+6.5%
Q3 2022$83,633,000
-13.8%
1,797,410
+5.7%
0.05%
-4.2%
Q2 2022$97,020,000
-6.7%
1,699,730
+0.1%
0.05%
+14.3%
Q1 2022$103,943,000
+82.8%
1,698,696
+56.3%
0.04%
+100.0%
Q4 2021$56,877,000
+11.8%
1,086,682
-20.4%
0.02%
+10.5%
Q3 2021$50,875,000
-8.7%
1,364,659
+0.0%
0.02%
-9.5%
Q2 2021$55,705,000
+40.5%
1,364,652
+16.8%
0.02%
+31.2%
Q1 2021$39,648,000
+396.9%
1,168,546
+90.1%
0.02%
+300.0%
Q2 2019$7,979,000
+6.6%
614,7000.0%0.00%0.0%
Q1 2019$7,487,000
+6.9%
614,7000.0%0.00%0.0%
Q4 2018$7,001,000
-34.6%
614,700
+24.7%
0.00%
-20.0%
Q3 2018$10,700,000
+9.0%
493,100
+94.9%
0.01%0.0%
Q2 2016$9,821,000
+39.6%
253,0000.0%0.01%
+25.0%
Q1 2016$7,033,000
-71.1%
253,000
-44.0%
0.00%
-66.7%
Q4 2015$24,308,000
+29.9%
451,900
-3.3%
0.01%
+33.3%
Q3 2015$18,719,000
+59.8%
467,500
+27.5%
0.01%
+80.0%
Q2 2015$11,716,000
+33.8%
366,7000.0%0.01%
+25.0%
Q1 2015$8,757,000
-0.6%
366,700
-26.5%
0.00%0.0%
Q4 2014$8,806,000
+14.7%
498,900
-10.9%
0.00%0.0%
Q3 2014$7,675,000
-45.0%
559,800
-32.4%
0.00%
-33.3%
Q2 2014$13,962,000
-8.6%
828,100
-1.5%
0.01%
-14.3%
Q1 2014$15,277,000840,3000.01%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2022
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 175,000$9,115,75010.70%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 317,856$16,547,5835.57%
Deep Track Capital, LP 2,600,000$135,434,0005.23%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,369,849$71,355,4343.86%
SILVERARC CAPITAL MANAGEMENT, LLC 208,730$10,872,7463.30%
DCF Advisers, LLC 107,157$5,581,8083.04%
Bellevue Group AG 3,170,250$165,138,3232.66%
Vahanian & Associates Financial Planning Inc. 15,217$792,6542.55%
Iron Triangle Partners LP 330,549$17,218,2972.52%
TANG CAPITAL MANAGEMENT LLC 300,000$15,627,0002.20%
View complete list of INTRA CELLULAR THERAPIES INC shareholders